Achilli F, Valagussa L, Valagussa F, De Vito G, Ferrario M, Cesana G
Divisione di Cardiologia, Azienda Ospedaliera, Ospedale San Gerardo, Monza.
G Ital Cardiol. 1997 Aug;27(8):790-802.
During the last decade, clinical trials consistently modified the therapeutic approach to coronary disease, and particularly to acute myocardial infarction. However, the magnitude of the contribution to the observed reduction in case fatality rates due the therapeutic improvement is still being debated.
To determine the real degree of implementation of the "suggested treatments" on clinical practice, and to evaluate their global effect on coronary mortality.
Analysis of the type of administered treatment in two consecutive series of acute coronary events, observed during the year 1986 (500 events) and 1989 (907 events), registered by the MONICA Project-Brianza Area. We evaluated: pre-coronary times; type of hospitalization; type of treatment before, during and after the event; occurrence of cardiac arrest and cardiopulmonary resuscitation both in and out of hospital; global and specific fatality rates at 28 days.
In the study period, overall coronary fatality rates changed from 29.4 to 23.6% (19% decrease-p < 0.05), fatality of confirmed AMI changed from 16.4 to 8.3% (49.4% decrease-p < 0.005); specific fatality for out of hospital cardiac arrest was unchanged (99%). Pre-coronary times were unmodified in the two periods of observation: hospitalization < 1 hr. in 20%, < 6 hr. in 50%, > 24 hr. in 10% of events. The percentage of cases admitted in CCU changed from 47.4 to 54.8% (from 71.6 to 86.4% of patients with confirmed AMI-p < 0.025). Thrombolysis in confirmed AMI changed from 29.3 to 43.2% (p < 0.001); antiplatelets treatment changed from 19.7 to 81.9% (p < 0.001); the use of betablockers went from 16.6 to 44% (p < 0.001) while the use of other agents was unmodified. Coronary arteriography and revascularization procedures continue to play a marginal role.
The MONICA registry experience shows that very important changes occurred in the treatment of coronary emergencies, particularly in the acute phase of myocardial infarction, suggesting that in our area, standardization of the therapeutic protocols might be responsible for the observed reduction of coronary fatality even though the advantages were observed only in hospitalized patients.
在过去十年中,临床试验不断改变冠心病的治疗方法,尤其是急性心肌梗死的治疗方法。然而,治疗改善对观察到的病死率降低的贡献程度仍存在争议。
确定“建议治疗”在临床实践中的实际实施程度,并评估其对冠心病死亡率的总体影响。
分析由莫尼卡项目-布里安扎地区登记的1986年(500例事件)和1989年(907例事件)连续两个系列急性冠脉事件中所给予治疗的类型。我们评估了:冠心病发作前时间;住院类型;事件发生前、期间和之后的治疗类型;院内心脏骤停和心肺复苏以及院外心脏骤停和心肺复苏的发生情况;28天时的总体和特定病死率。
在研究期间,总体冠心病病死率从29.4%降至23.6%(下降19%,p<0.05),确诊急性心肌梗死的病死率从16.4%降至8.3%(下降49.4%,p<0.005);院外心脏骤停的特定病死率未变(99%)。在两个观察期内,冠心病发作前时间未改变:20%的事件住院时间<1小时,50%的事件住院时间<6小时,10%的事件住院时间>24小时。入住冠心病监护病房的病例百分比从47.4%升至54.8%(确诊急性心肌梗死患者从71.6%升至86.4%,p<0.025)。确诊急性心肌梗死时的溶栓治疗从29.3%升至43.2%(p<0.001);抗血小板治疗从19.7%升至81.9%(p<0.001);β受体阻滞剂的使用从16.6%升至44%(p<0.001),而其他药物的使用未改变。冠状动脉造影和血运重建手术继续发挥次要作用。
莫尼卡登记处的经验表明,冠心病急症治疗发生了非常重要的变化,尤其是在心肌梗死急性期,这表明在我们地区,治疗方案的标准化可能是观察到的冠心病病死率降低的原因,尽管优势仅在住院患者中观察到。